3,435 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by Carbahal Olsen Financial Services Group LLC

Carbahal Olsen Financial Services Group LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 3,435 shares of the biopharmaceutical company's stock, valued at approximately $317,000. Gilead Sciences makes up about 0.3% of Carbahal Olsen Financial Services Group LLC's investment portfolio, making the stock its 23rd largest holding.

Several other hedge funds have also recently modified their holdings of GILD. FMR LLC increased its position in Gilead Sciences by 21.6% during the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after purchasing an additional 7,157,113 shares during the last quarter. Wellington Management Group LLP lifted its position in Gilead Sciences by 3.1% in the fourth quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock valued at $3,293,822,000 after buying an additional 1,058,331 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Gilead Sciences by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock valued at $2,608,337,000 after acquiring an additional 749,047 shares during the last quarter. Norges Bank acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $1,789,254,000. Finally, Invesco Ltd. boosted its position in shares of Gilead Sciences by 12.9% during the 4th quarter. Invesco Ltd. now owns 11,277,915 shares of the biopharmaceutical company's stock worth $1,041,741,000 after purchasing an additional 1,292,399 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 137,676 shares of the firm's stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $102.22, for a total value of $14,073,240.72. Following the completion of the sale, the chief financial officer now owns 171,223 shares of the company's stock, valued at $17,502,415.06. This trade represents a 44.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last three months, insiders sold 302,785 shares of company stock valued at $30,540,875. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Stock Up 0.2 %

Shares of GILD traded up $0.24 during midday trading on Wednesday, reaching $105.75. 3,860,128 shares of the stock were exchanged, compared to its average volume of 7,497,675. The company has a market cap of $131.68 billion, a price-to-earnings ratio of 285.81, a P/E/G ratio of 0.71 and a beta of 0.32. The firm has a 50 day simple moving average of $109.17 and a 200-day simple moving average of $97.82. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.99%. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences's dividend payout ratio is 854.05%.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and upped their price target for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. The Goldman Sachs Group raised their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a report on Tuesday. They set an "overweight" rating and a $125.00 target price on the stock. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Finally, Wells Fargo & Company upped their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Ten equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and four have given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $106.92.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.